STOP-HCV is a Medical Research Council (MRC) funded consortium which aims to use patient information to establish the most effective and cost effective treatments for patients with Hepatitis C Virus.
The STOP-HCV consortium is formed of 21 partners representing academia, industry and the Hepatitis C Trust.
Gilead Sciences BOSON trial - clinical findings will be presented by Professor Graham Foster at the annual European Association for the Study of Liver Disease meeting in Vienna, 22-26 April 2015.
'HCV Research Consortia: A 10,000 UK patient cohort delibvering translational research' - STOP-HCV will be presenting at this BVHG Showcase Event in Manchester on 5 June 2015
Gilead Sciences BOSON trial - the Clinical Research Network's 'Spotlight on hepatitis research' highlights the importance of the academic-industrial collaboration within STOP-HCV.
STOP-HCV award now active
The official start date for STOP-HCV was 16th September 2013. Work has now begun to meet the consortiums aims.